Impel NeuroPharma (NSDQ:IMPL), a biopharma founded in 2008, has won FDA approval for Trudhesa (dihydroergotamine mesylate) nasal spray as an acute migraine therapy. The Seattle-based company intends to launch the drug, formerly known as INP104, in early October 2021. Impel plans to price the drug between $600 and $850 for a package with four doses.…